The goal of the Center for Pediatric Tumor Cell Atlas (CPTCA) is to molecularly characterize the genome, transcriptome, methylome and chromatin accessibility at critical transition points in 3 deadly pediatric cancers: pediatric high grade glioma (pHGG), high risk neuroblastoma (HR NB) and very high-risk B-cell ALL (VHR ALL). The transitions are those that occur over time: 1. in response to therapy and 2. at recurrence/relapse and spatially within the native tumor architecture.
What are the goals of this project?
The goal of this project is to acquire, process and characterize pediatric high-grade glioma (pHGG) biospecimens for the CPTCA examining the critical genomic transitions from diagnosis to relapse.
What is the impact of this project?
Relapsed pediatric high-grade glioma, high-risk neuroblastoma and VHR-ALL account for more than half of all pediatric cancer deaths. In order to advance novel therapies for children with these tumors, there is a need to fully genomically characterize and query the tumor’s responses to therapy and the development of therapy resistance with both spatial and temporal single cell resolution. The depth of knowledge these analyses provide will be markedly influenced by the integrity and characterization of the biospecimens. Therefore, our multi-disciplinary team of oncologists, pathologists, surgeons and biorepository personnel is uniquely poised to ensure that the biospecimens of the CPTCA HTA are complete, of utmost quality and fully annotated with all available clinical co-variates. In addition, our established biorepository and historical commitment to both resource and data sharing guarantee that the entire research and patient community will benefit.
Why is the CBTN request important to this project?
The Children's Brain Tumor Network is able to provide free and open access to tumor biospecimens and clinical and genomic data to researchers throughout the world.
The Children's Brain Tumor Network contributed to this project by providing samples, genomic data and imaging data.
Kristina A. Cole, MD, PhD
Kristina Cole, MD, PhD is a pediatric oncologist who has dedicated her career to translational and clinical research, combining her expertise in molecular pathology, cancer genomics, and developmental therapeutics to identify novel treatments for children with cancer. The long-term goal of Dr. Cole’
Children’s Hospital of Philadelphia
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test